About this resource:
Source: The Cochrane Collaborative
Last Reviewed: May 2016
In this Cochrane systematic review, the Cochrane Collaborative found that fixed-dose combinations (FDCs) of anti-tuberculosis medicines may have similar effects as single‐drug formulations for treating people with newly diagnosed pulmonary tuberculosis. The treatment for pulmonary tuberculosis in new patients includes 4 medicines taken by mouth for 6 months, sometimes as FDCs that are combined in 1 tablet and sometimes taken separately as single-drug formulations. Researchers found little to no difference in outcomes for people taking FDCs compared with those taking single-drug formulations.
Objectives related to this resource (1)
Gallardo, C.R., Rigau Comas, D., Valderrama Rodríguez, A., Roqué i Figuls, M., Parker, L.A., Caylà, J. & Bonfill Cosp, X. Fixed‐dose combinations of drugs versus single‐drug formulations for treating pulmonary tuberculosis. Cochrane Database of Systematic Reviews, 2016 (5). DOI: 10.1002/14651858.CD009913.pub2